{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T21:22:43Z","timestamp":1777152163344,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Danish Council for Independent Research, Technology and Production","award":["12-126289"],"award-info":[{"award-number":["12-126289"]}]},{"name":"Danish Council for Independent Research, Technology and Production","award":["7017-00079B"],"award-info":[{"award-number":["7017-00079B"]}]},{"name":"U.S. National Institutes of General Medical Science","award":["GM098175-17"],"award-info":[{"award-number":["GM098175-17"]}]},{"name":"U.S. National Institutes of General Medical Science","award":["GM098175-17"],"award-info":[{"award-number":["GM098175-17"]}]},{"name":"European Union Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement","award":["765147"],"award-info":[{"award-number":["765147"]}]},{"name":"European Union Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement","award":["765147"],"award-info":[{"award-number":["765147"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Antimicrobial peptides (AMPs) are central components of the innate immune system providing protection against pathogens. Yet, serum and tissue concentrations vary between individuals and with disease conditions. We demonstrate that the human AMP LL-37 lowers the susceptibility to vancomycin in the community-associated methicillin-resistant\n                    <jats:italic>S. aureus<\/jats:italic>\n                    (CA-MRSA) strain FPR3757 (USA300). Vancomycin is used to treat serious MRSA infections, but treatment failures occur despite MRSA strains being tested susceptible according to standard susceptibility methods. Exposure to physiologically relevant concentrations of LL-37 increased the minimum inhibitory concentration (MIC) of\n                    <jats:italic>S. aureus<\/jats:italic>\n                    towards vancomycin by 75%, and resulted in shortened lag-phase and increased colony formation at sub-inhibitory concentrations of vancomycin. Computer simulations using a mathematical antibiotic treatment model indicated that a small increase in MIC might decrease the efficacy of vancomycin in clearing a\n                    <jats:italic>S. aureus<\/jats:italic>\n                    infection. This prediction was supported in a\n                    <jats:italic>Galleria mellonella<\/jats:italic>\n                    infection model, where exposure of\n                    <jats:italic>S. aureus<\/jats:italic>\n                    to LL-37 abolished the antimicrobial effect of vancomycin. Thus, physiological relevant concentrations of LL-37 reduce susceptibility to vancomycin, indicating that tissue and host specific variations in LL-37 concentrations may influence vancomycin susceptibility in vivo.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-69962-4","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T06:03:35Z","timestamp":1596521015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Human antimicrobial peptide, LL-37, induces non-inheritable reduced susceptibility to vancomycin in Staphylococcus aureus"],"prefix":"10.1038","volume":"10","author":[{"given":"Cathrine","family":"Friberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob Krause","family":"Haaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00eblle","family":"Fait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce R.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"Ingmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"69962_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrmicro3380","volume":"13","author":"JM Blair","year":"2015","unstructured":"Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 13, 42\u201351 (2015).","journal-title":"Nat. Rev. Microbiol."},{"key":"69962_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ijmm.2013.02.009","volume":"303","author":"G Cox","year":"2013","unstructured":"Cox, G. & Wright, G. D. Intrinsic antibiotic resistance: mechanisms, origins, challenges and solutions. Int. J. Med. Microbiol. 303, 287\u2013292 (2013).","journal-title":"Int. J. Med. Microbiol."},{"key":"69962_CR3","first-page":"e02268-e2214","volume":"6","author":"J Haaber","year":"2015","unstructured":"Haaber, J. et al. Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure. Mbio 6, e02268-e2214 (2015).","journal-title":"Mbio"},{"key":"69962_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nrmicro2200","volume":"7","author":"HF Chambers","year":"2009","unstructured":"Chambers, H. F. & DeLeo, F. R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7, 629\u2013641 (2009).","journal-title":"Nat. Rev. Microbiol."},{"key":"69962_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/cir935","volume":"54","author":"S Van Hal","year":"2012","unstructured":"Van Hal, S., Lodise, T. P. & Paterson, D. L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54, 755\u2013771 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"69962_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1128\/CMR.00042-09","volume":"23","author":"BP Howden","year":"2010","unstructured":"Howden, B. P., Davies, J. K., Johnson, P. D., Stinear, T. P. & Grayson, M. L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23, 99\u2013139 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"69962_CR7","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1128\/AAC.00209-07","volume":"51","author":"M Meehl","year":"2007","unstructured":"Meehl, M., Herbert, S., G\u00f6tz, F. & Cheung, A. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 51, 2679\u20132689 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69962_CR8","doi-asserted-by":"publisher","first-page":"7103","DOI":"10.1128\/JB.185.24.7103-7110.2003","volume":"185","author":"K Sieradzki","year":"2003","unstructured":"Sieradzki, K. & Tomasz, A. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J. Bacteriol. 185, 7103\u20137110 (2003).","journal-title":"J. Bacteriol."},{"key":"69962_CR9","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1128\/AAC.48.10.3749-3757.2004","volume":"48","author":"JL Koehl","year":"2004","unstructured":"Koehl, J. L. et al. Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 48, 3749\u20133757 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69962_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1086\/381202","volume":"38","author":"BP Howden","year":"2004","unstructured":"Howden, B. P. et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38, 521\u2013528 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"69962_CR11","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1128\/AAC.00113-08","volume":"52","author":"T Lodise","year":"2008","unstructured":"Lodise, T. et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52, 3315\u20133320 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69962_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jinf.2008.04.003","volume":"57","author":"JC Dombrowski","year":"2008","unstructured":"Dombrowski, J. C. & Winston, L. G. Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections. J. Infect. 57, 110\u2013115 (2008).","journal-title":"J. Infect."},{"key":"69962_CR13","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1128\/AAC.47.4.1262-1266.2003","volume":"47","author":"MR Moore","year":"2003","unstructured":"Moore, M. R., Perdreau-Remington, F. & Chambers, H. F. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob. Agents Chemother. 47, 1262\u20131266 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69962_CR14","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s10529-005-0936-5","volume":"27","author":"K De Smet","year":"2005","unstructured":"De Smet, K. & Contreras, R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol. Lett. 27, 1337\u20131347 (2005).","journal-title":"Biotechnol. Lett."},{"key":"69962_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1432-1033.1996.0325z.x","volume":"238","author":"GH Gudmundsson","year":"1996","unstructured":"Gudmundsson, G. H. et al. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur. J. Biochem. 238, 325\u2013332 (1996).","journal-title":"Eur. J. Biochem."},{"key":"69962_CR16","first-page":"249","volume":"208","author":"H Komatsuzawa","year":"2006","unstructured":"Komatsuzawa, H. et al. Innate defences against methicillin-resistant Staphylococcus aureus (MRSA) infection. J. Pathol. J. Pathol. Soc. G. B. Irel. 208, 249\u2013260 (2006).","journal-title":"J. Pathol. J. Pathol. Soc. G. B. Irel."},{"key":"69962_CR17","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1128\/IAI.73.8.5241-5244.2005","volume":"73","author":"BE Menzies","year":"2005","unstructured":"Menzies, B. E. & Kenoyer, A. Staphylococcus aureus infection of epidermal keratinocytes promotes expression of innate antimicrobial peptides. Infect. Immun. 73, 5241\u20135244 (2005).","journal-title":"Infect. Immun."},{"key":"69962_CR18","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1084\/jem.192.7.1069","volume":"192","author":"D Yang","year":"2000","unstructured":"Yang, D. et al. LL-37, the neutrophil granule\u2014and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor\u2013like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192, 1069\u20131074 (2000).","journal-title":"J. Exp. Med."},{"key":"69962_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0022-1759(97)00084-7","volume":"206","author":"O S\u00f8rensen","year":"1997","unstructured":"S\u00f8rensen, O., Cowland, J. B., Askaa, J. & Borregaard, N. An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J. Immunol. Methods 206, 53\u201359 (1997).","journal-title":"J. Immunol. Methods"},{"key":"69962_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jcf.2003.12.008","volume":"3","author":"CI-U Chen","year":"2004","unstructured":"Chen, C.I.-U., Schaller-Bals, S., Paul, K. P., Wahn, U. & Bals, R. \u03b2-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J. Cyst. Fibros. 3, 45\u201350 (2004).","journal-title":"J. Cyst. Fibros."},{"key":"69962_CR21","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1164\/ajrccm.165.7.200110-020","volume":"165","author":"S Schaller-Bals","year":"2002","unstructured":"Schaller-Bals, S., Schulze, A. & Bals, R. Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. Am. J. Respir. Crit. Care Med. 165, 992\u2013995 (2002).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"69962_CR22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0140-6736(06)68231-7","volume":"367","author":"BA Diep","year":"2006","unstructured":"Diep, B. A. et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 367, 731\u2013739 (2006).","journal-title":"Lancet"},{"key":"69962_CR23","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1128\/AAC.48.10.3670-3676.2004","volume":"48","author":"RR Regoes","year":"2004","unstructured":"Regoes, R. R. et al. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob. Agents Chemother. 48, 3670\u20133676 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69962_CR24","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1128\/AAC.49.4.1483-1494.2005","volume":"49","author":"C Wiuff","year":"2005","unstructured":"Wiuff, C. et al. Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob. Agents Chemother. 49, 1483\u20131494 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69962_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev.mi.03.100149.002103","volume":"3","author":"J Monod","year":"1949","unstructured":"Monod, J. The growth of bacterial cultures. Annu. Rev. Microbiol. 3, 371\u2013394 (1949).","journal-title":"Annu. Rev. Microbiol."},{"key":"69962_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1086\/282825","volume":"107","author":"FM Stewart","year":"1973","unstructured":"Stewart, F. M. & Levin, B. R. Resource partitioning and the outcome of interspecific competition: a model and some general considerations. Am. Nat. 107, 171\u2013198 (1973).","journal-title":"Am. Nat."},{"key":"69962_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/infdis\/jir270","volume":"204","author":"NE Holmes","year":"2011","unstructured":"Holmes, N. E. et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J. Infect. Dis. 204, 340\u2013347 (2011).","journal-title":"J. Infect. Dis."},{"key":"69962_CR28","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1345\/aph.1R158","volume":"46","author":"A Horey","year":"2012","unstructured":"Horey, A., Mergenhagen, K. A. & Mattappallil, A. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran\u2019s population: a retrospective analysis. Ann. Pharmacother. 46, 1477\u20131483 (2012).","journal-title":"Ann. Pharmacother."},{"key":"69962_CR29","first-page":"e4392","volume":"70","author":"N Ramarao","year":"2012","unstructured":"Ramarao, N., Nielsen-Leroux, C. & Lereclus, D. The insect Galleria mellonella as a powerful infection model to investigate bacterial pathogenesis. J. Vis. Exp. JoVE 70, e4392 (2012).","journal-title":"J. Vis. Exp. JoVE"},{"key":"69962_CR30","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1128\/JCM.00580-11","volume":"49","author":"GV Doern","year":"2011","unstructured":"Doern, G. V. & Brecher, S. M. The clinical predictive value (or lack thereof) of the results of in vitro antimicrobial susceptibility tests. J. Clin. Microbiol. 49, S11\u2013S14 (2011).","journal-title":"J. Clin. Microbiol."},{"key":"69962_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ebiom.2017.05.026","volume":"20","author":"SC Ersoy","year":"2017","unstructured":"Ersoy, S. C. et al. Correcting a fundamental flaw in the paradigm for antimicrobial susceptibility testing. EBioMedicine 20, 173\u2013181 (2017).","journal-title":"EBioMedicine"},{"key":"69962_CR32","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/femsre\/fux004","volume":"41","author":"D Hughes","year":"2017","unstructured":"Hughes, D. & Andersson, D. I. Environmental and genetic modulation of the phenotypic expression of antibiotic resistance. FEMS Microbiol. Rev. 41, 374\u2013391 (2017).","journal-title":"FEMS Microbiol. Rev."},{"key":"69962_CR33","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.ebiom.2015.08.012","volume":"2","author":"JZ Kubicek-Sutherland","year":"2015","unstructured":"Kubicek-Sutherland, J. Z. et al. Host-dependent induction of transient antibiotic resistance: a prelude to treatment failure. EBioMedicine 2, 1169\u20131178 (2015).","journal-title":"EBioMedicine"},{"key":"69962_CR34","doi-asserted-by":"publisher","first-page":"e00410","DOI":"10.1128\/mSphere.00410-17","volume":"2","author":"G Sakoulas","year":"2017","unstructured":"Sakoulas, G., Kumaraswamy, M., Kousha, A. & Nizet, V. Interaction of antibiotics with innate host defense factors against Salmonella enterica serotype newport. mSphere 2, e00410\u2013e00417 (2017).","journal-title":"mSphere"},{"key":"69962_CR35","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu, C. et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52, e18\u2013e55 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"69962_CR36","doi-asserted-by":"publisher","first-page":"8331","DOI":"10.1073\/pnas.1400352111","volume":"111","author":"P Ankomah","year":"2014","unstructured":"Ankomah, P. & Levin, B. R. Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections. Proc. Natl. Acad. Sci. USA 111, 8331\u20138338. https:\/\/doi.org\/10.1073\/pnas.1400352111 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69962_CR37","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.tim.2017.07.005","volume":"25","author":"BR Levin","year":"2017","unstructured":"Levin, B. R., Baquero, F., Ankomah, P. P. & McCall, I. C. Phagocytes, antibiotics, and self-limiting bacterial infections. Trends Microbiol. 25, 878\u2013892. https:\/\/doi.org\/10.1016\/j.tim.2017.07.005 (2017).","journal-title":"Trends Microbiol."},{"key":"69962_CR38","doi-asserted-by":"publisher","first-page":"628289","DOI":"10.1155\/2014\/628289","volume":"2014","author":"A Batycka-Baran","year":"2014","unstructured":"Batycka-Baran, A., Maj, J., Wolf, R. & Szepietowski, J. The new insight into the role of antimicrobial proteins-alarmins in the immunopathogenesis of psoriasis. J. Immunol. Res. 2014, 628289 (2014).","journal-title":"J. Immunol. Res."},{"key":"69962_CR39","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1056\/NEJMoa021481","volume":"347","author":"PY Ong","year":"2002","unstructured":"Ong, P. Y. et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347, 1151\u20131160 (2002).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69962-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69962-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69962-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T10:09:44Z","timestamp":1670321384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69962-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["69962"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-69962-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2019.12.24.886184","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,4]]},"assertion":[{"value":"22 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13121"}}